Dr. Lorenz Raber recaps the PACMAN-AMI study and how the PCSK9 inhibitor alirocumab can aid in coronary plaque regression.
advertisement
PCSK9i Reduces Plaque Burden in Coronary Arteries
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Dr. Lorenz Raber recaps the PACMAN-AMI study and how the PCSK9 inhibitor alirocumab can aid in coronary plaque regression.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?